A BILL 
To support fungal disease research, incentivize fungal vaccine 
development, discover new antifungal therapies and 
diagnostics, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) IN GENERAL.—This Act may be cited as the 
4
‘‘Finding Orphan-disease Remedies With Antifungal Re-
5
search and Development Act of 2021’’ or the ‘‘FOR-
6
WARD Act of 2021’’. 
7
(b) TABLE OF CONTENTS.—The table of contents for 
8
this Act is as follows: 
9
01:30 Oct 14, 2021
H5566
2 
•HR 5566 IH
Sec. 1. Short title; table of contents. 
Sec. 2. Continuing support for research on endemic fungal diseases. 
Sec. 3. Endemic Fungal Disease Working Group. 
Sec. 4. FDA guidance for industry on development of diagnostics and 
antifungal drugs and vaccines for Valley Fever. 
Sec. 5. Priority review; fast track product. 
Sec. 6. Priority review vouchers to encourage treatments and vaccines for Val-
ley Fever. 
Sec. 7. Combating Antimicrobial Resistance Biopharmaceutical Accelerator Pro-
gram. 
SEC. 2. CONTINUING SUPPORT FOR RESEARCH ON EN-
1
DEMIC FUNGAL DISEASES. 
2
The Public Health Service Act is amended by insert-
3
ing after section 447C of such Act (42 U.S.C. 285f–4) 
4
the following new section: 
5
‘‘SEC. 447D. ENDEMIC FUNGAL DISEASES. 
6
‘‘(a) IN GENERAL.—The Director of the Institute 
7
shall— 
8
‘‘(1) continue to conduct or support epidemio-
9
logical, basic, translational, and clinical research, 
10
such as vaccine development, related to endemic 
11
fungal diseases, including coccidioidomycosis (com-
12
monly known as and referred to in this section as 
13
‘Valley Fever’); and 
14
‘‘(2) subject to the availability of appropria-
15
tions, make grants to, or enter into contracts with, 
16
public or nonprofit private entities to conduct such 
17
research. 
18
‘‘(b) REPORTS.—The Director of the Institute shall 
19
ensure that each triennial report under section 403 in-
20
01:30 Oct 14, 2021
H5566
3 
•HR 5566 IH
cludes information on actions undertaken by the National 
1
Institutes of Health to carry out subsection (a) with re-
2
spect to endemic fungal diseases, including Valley Fever. 
3
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—In ad-
4
dition to other amounts available for the purposes of car-
5
rying out this section, there is authorized to be appro-
6
priated to carry out this section $20,000,000 for each of 
7
fiscal years 2022 through 2026 for such purpose.’’. 
8
SEC. 3. ENDEMIC FUNGAL DISEASE WORKING GROUP. 
9
(a) ESTABLISHMENT.—The Secretary of Health and 
10
Human Services (in this section referred to as the ‘‘Sec-
11
retary’’) shall establish a working group, to be known as 
12
the Endemic Fungal Disease Working Group (referred to 
13
in this section as the ‘‘Working Group’’), comprised of 
14
representatives of appropriate Federal agencies and other 
15
non-Federal entities— 
16
(1) to provide expertise and to review all efforts 
17
within the Department of Health and Human Serv-
18
ices related to endemic fungal disease; 
19
(2) to help ensure interagency coordination and 
20
minimize overlap with respect to such disease; and 
21
(3) to examine research priorities with respect 
22
to such disease. 
23
(b) RESPONSIBILITIES.—The Working Group shall— 
24
01:30 Oct 14, 2021
H5566
4 
•HR 5566 IH
(1) not later than 2 years after the date of en-
1
actment of this Act, develop or update a summary 
2
of— 
3
(A) ongoing endemic fungal disease re-
4
search, including research related to causes, 
5
prevention (such as vaccine development), treat-
6
ment, surveillance, diagnosis, diagnostics, dura-
7
tion of illness, and intervention for individuals 
8
with an endemic fungal disease; 
9
(B) advances made pursuant to such re-
10
search; 
11
(C) the impact of viral respiratory ill-
12
nesses, including COVID–19, and fungal lung 
13
diseases and pneumonias; 
14
(D) Federal activities related to endemic 
15
fungal disease, including— 
16
(i) epidemiological activities related to 
17
endemic fungal disease; and 
18
(ii) basic, clinical, and translational 
19
endemic fungal disease research related to 
20
the pathogenesis, prevention (such as vac-
21
cine development), diagnosis, and treat-
22
ment of endemic fungal disease; 
23
(E) gaps in endemic fungal disease re-
24
search described in subparagraph (D)(ii); 
25
01:30 Oct 14, 2021
H5566
5 
•HR 5566 IH
(F) the Working Group’s meetings re-
1
quired under subsection (d); and 
2
(G) the comments received by the Working 
3
Group; 
4
(2) make recommendations, including a pro-
5
posed strategy related to development of thera-
6
peutics and vaccines, to the Secretary regarding any 
7
appropriate changes or improvements related to ac-
8
tivities described in paragraph (1); and 
9
(3) in implementing this subsection, solicit 
10
input from States, localities, and nongovernmental 
11
entities, including organizations representing pa-
12
tients, health care providers, researchers, and indus-
13
try regarding scientific advances, research questions, 
14
and surveillance activities. 
15
(c) MEMBERSHIP.—The members of the Working 
16
Group shall represent a diversity of scientific disciplines 
17
and views and shall be composed of the following mem-
18
bers: 
19
(1) FEDERAL MEMBERS.—Seven Federal mem-
20
bers, consisting of one or more representatives of 
21
each of the following: 
22
(A) The Office of the Assistant Secretary 
23
for Health. 
24
(B) The Food and Drug Administration. 
25
01:30 Oct 14, 2021
H5566
6 
•HR 5566 IH
(C) The Centers for Disease Control and 
1
Prevention. 
2
(D) The National Institutes of Health. 
3
(E) Such other agencies and offices of the 
4
Department of Health and Human Services as 
5
the Secretary determines appropriate. 
6
(2) NON-FEDERAL
PUBLIC
MEMBERS.—Seven 
7
non-Federal public members, consisting of represent-
8
atives of the following categories: 
9
(A) Physicians and other medical providers 
10
with experience in diagnosing and treating en-
11
demic fungal disease. 
12
(B) Scientists or researchers with exper-
13
tise. 
14
(C) Patients and their family members. 
15
(D) Nonprofit organizations that advocate 
16
for patients with respect to endemic fungal dis-
17
ease. 
18
(E) Other individuals whose expertise is 
19
determined by the Secretary to be beneficial to 
20
the functioning of the Working Group. 
21
(d) MEETINGS.—The Working Group shall meet an-
22
nually. 
23
(e) REPORTING.—Not later than 2 years after the 
24
date of enactment of this Act, and every 2 years thereafter 
25
01:30 Oct 14, 2021
H5566
7 
•HR 5566 IH
until termination of the Working Group pursuant to sub-
1
section (g), the Working Group shall— 
2
(1) submit a report on its activities under sub-
3
section (b)(1) and any recommendations under sub-
4
section (b)(2) to the Secretary, the Committee on 
5
Energy and Commerce of the House of Representa-
6
tives, and the Committee on Health, Education, 
7
Labor, and Pensions of the Senate; and 
8
(2) make such report publicly available on the 
9
internet website of the Department of Health and 
10
Human Services. 
11
(f) APPLICABILITY OF FACA.—The Working Group 
12
shall be treated as an advisory committee subject to the 
13
Federal Advisory Committee Act (5 U.S.C. App.). 
14
(g) SUNSET.—The Working Group under this section 
15
shall terminate 5 years after the date of enactment of this 
16
Act. 
17
(h) ENDEMIC FUNGAL DISEASE DEFINED.—In this 
18
section, the term ‘‘endemic fungal disease’’ means blasto-
19
mycosis, 
coccidioidomycosis, 
histoplasmosis, 
and 
20
sporotrichosis. 
21
01:30 Oct 14, 2021
H5566
8 
•HR 5566 IH
SEC. 4. FDA GUIDANCE FOR INDUSTRY ON DEVELOPMENT 
1
OF DIAGNOSTICS AND ANTIFUNGAL DRUGS 
2
AND VACCINES FOR VALLEY FEVER. 
3
(a) DRAFT GUIDANCE.—Not later than 2 years after 
4
the date of the enactment of this Act, the Secretary of 
5
Health and Human Services, acting through the Commis-
6
sioner of Food and Drugs, shall issue draft guidance for 
7
industry for the purposes of assisting entities seeking ap-
8
proval under the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 301 et seq.) or licensure under section 351 
10
of the Public Health Service Act (42 U.S.C. 262) of 
11
antifungal therapies, diagnostics, or vaccines, specifically 
12
therapies, diagnostics, and vaccines designed to diagnose, 
13
treat, or prevent coccidioidomycosis (commonly known as 
14
Valley Fever). 
15
(b) FINAL GUIDANCE.—Not later than 18 months 
16
after the close of the public comment period on the draft 
17
guidance issued pursuant to subsection (a), the Secretary 
18
of Health and Human Services, acting through the Com-
19
missioner of Food and Drugs, shall finalize the draft guid-
20
ance. 
21
(c) WORKSHOPS; GOOD GUIDANCE PRACTICES.—In 
22
developing and issuing the guidance required by this sec-
23
tion, the Secretary of Health and Human Services shall 
24
hold at least 2 public workshops. 
25
01:30 Oct 14, 2021
H5566
9 
•HR 5566 IH
SEC. 5. PRIORITY REVIEW; FAST TRACK PRODUCT. 
1
(a) PRIORITY REVIEW.— 
2
(1) IN GENERAL.—Section 524A(a) of the Fed-
3
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
4
360n–1(a)) is amended by striking ‘‘then the Sec-
5
retary shall give priority review to the first applica-
6
tion submitted for approval for such drug under sec-
7
tion 505(b)’’ and inserting ‘‘or if the drug is a bio-
8
logical product intended to treat coccidioidomycosis, 
9
then the Secretary shall give priority review to the 
10
first application submitted for approval for such 
11
drug under section 505(b) of this Act or section 
12
351(a) of the Public Health Service Act’’. 
13
(2) APPLICABILITY.—The amendment made by 
14
paragraph (1) applies to an application submitted 
15
under section 351(a) of the Public Health Service 
16
Act (42 U.S.C. 262(a)) only if such application is 
17
submitted on or after the date of enactment of this 
18
Act. 
19
(b) FAST TRACK PRODUCT.—Section 506(b)(1) of 
20
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
21
356(b)(1)) is amended by striking ‘‘or if the Secretary 
22
designates the drug as a qualified infectious disease prod-
23
uct under section 505E(d)’’ and inserting ‘‘if the Sec-
24
retary designates the drug as a qualified infectious disease 
25
01:30 Oct 14, 2021
H5566
10 
•HR 5566 IH
product under section 505E(d), or if the drug is a biologi-
1
cal product intended to treat coccidioidomycosis’’. 
2
SEC. 6. PRIORITY REVIEW VOUCHERS TO ENCOURAGE 
3
TREATMENTS AND VACCINES FOR VALLEY 
4
FEVER. 
5
Section 524(a)(3) of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended— 
7
(1) by redesignating subparagraph (S) as sub-
8
paragraph (T); and 
9
(2) by inserting after subparagraph (R) the fol-
10
lowing: 
11
‘‘(S) Coccidioidomycosis.’’. 
12
SEC. 7. COMBATING ANTIMICROBIAL RESISTANCE BIO-
13
PHARMACEUTICAL ACCELERATOR PROGRAM. 
14
Paragraph (4) of section 319L(c) of the Public 
15
Health Service Act (42 U.S.C. 247d–7e(c)) is amended 
16
by adding at the end the following: 
17
‘‘(G) COMBATING ANTIMICROBIAL RESIST-
18
ANCE BIOPHARMACEUTICAL ACCELERATOR PRO-
19
GRAM.— 
20
‘‘(i) IN
GENERAL.—The Secretary, 
21
acting through the Director of BARDA, 
22
shall implement strategic initiatives, to be 
23
known as the Combating Antimicrobial Re-
24
sistance 
Biopharmaceutical 
Accelerator 
25
01:30 Oct 14, 2021
H5566
11 
•HR 5566 IH
Program, including by building on existing 
1
programs and by awarding contracts, 
2
grants, and cooperative agreements, or en-
3
tering into other transactions— 
4
‘‘(I) to optimize the use of 
5
antimicrobials in human and animal 
6
health settings; 
7
‘‘(II) to support innovative can-
8
didate products in preclinical and clin-
9
ical development that reduce anti-
10
microbial resistance; and 
11
‘‘(III) to support research with 
12
respect to infection prevention and 
13
control to slow the spread of resistant 
14
bacteria, fungi, and viruses. 
15
‘‘(ii) REFERENCES.—Except as other-
16
wise specified, any reference to the Com-
17
bating Antibiotic Resistant Bacteria Bio-
18
pharmaceutical Accelerator or the CARB- 
19
X program in any statute, Executive order, 
20
rule, regulation, directive, or other Federal 
21
document is deemed to be a reference to 
22
the Combating Antimicrobial Resistance 
23
Biopharmaceutical Accelerator Program 
24
under this subparagraph. 
25
01:30 Oct 14, 2021
H5566
12 
•HR 5566 IH
‘‘(iii) AUTHORIZATION OF APPROPRIA-
1
TIONS.— 
2
‘‘(I) IN GENERAL.—To carry out 
3
the program under clause (i), there is 
4
authorized 
to 
be 
appropriated 
5
$500,000,000 for the period of fiscal 
6
years 2022 through 2026, to remain 
7
available until expended. 
8
‘‘(II) 
REQUIREMENT.—Of 
the 
9
amounts made available to carry out 
10
the program under clause (i) for the 
11
period of fiscal years 2022 through 
12
2026, not less than 10 percent shall 
13
be used to support antifungal product 
14
development.’’. 
15
Æ 
01:30 Oct 14, 2021
H5566
